|
Aug 8
|
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
|
|
Aug 6
|
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
|
|
Jul 22
|
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink
|
|
Jul 11
|
Capricor Therapeutics Hammered On A Surprise FDA Rejection
|
|
Jul 11
|
Sector Update: Health Care Stocks Slide Friday Afternoon
|
|
Jul 11
|
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday After Surprise Tariff Hikes
|
|
Jul 11
|
Capricor Therapeutics Says FDA Requires Additional Data on Deramiocel; Shares Fall Pre-Bell
|
|
Jul 11
|
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
|
|
Jun 30
|
US High Growth Tech Stocks with Promising Potential
|
|
Jun 26
|
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
|
|
Apr 21
|
Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ...
|
|
Feb 17
|
High Growth Tech Stocks In The United States To Watch
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 2
|
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
|